{"content":"<li class=\"n-box-item date-title\" data-end=\"1465271999\" data-start=\"1465185600\" data-txt=\"Sunday, December 22, 2019\">Monday, June  6, 2016</li><li class=\"n-box-item sa-box-item\" data-id=\"3187507\" data-ts=\"1465254395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BEP\" target=\"_blank\">BEP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187507-brookfield-renewable-announces-c-800m-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brookfield Renewable announces C$800M equity offering</a></h4><ul>     <li>Brookfield Renewable Partners (NYSE:<a href=\"https://seekingalpha.com/symbol/BEP\" title=\"Brookfield Renewable Partners L.P.\">BEP</a>) <font color=\"red\">-1.6%</font> AH after saying it plans to issue 10.655M limited partner units on a bought-deal basis at C$37.55/unit, with an underwriters option to purchase up to an additional 1.598M units.</li>     <li>In addition, Brookfield Asset Management (NYSE:<a href=\"https://seekingalpha.com/symbol/BAM\" title=\"Brookfield Asset Management Inc.\">BAM</a>) and related entities say they will purchase ~11.1M BEP units concurrent  with the offering; aggregate gross proceeds of the offering and concurrent private placement will total slightly more than C$800M.</li>     <li>BEP says it plans to use the proceeds to pay down debt and for general corporate purposes; following the offering and concurrent private placement, BAM's interest in  BEP will be ~61.4%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187507\" data-linked=\"Brookfield Renewable announces C$800M equity offering\" data-tweet=\"$BEP $BEP $BAM - Brookfield Renewable announces C$800M equity offering https://seekingalpha.com/news/3187507-brookfield-renewable-announces-c-800m-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3187507-brookfield-renewable-announces-c-800m-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187503\" data-ts=\"1465250628\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRPT\" target=\"_blank\">SRPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187503-sarepta-soars-fda-requests-dystrophin-data-prior-to-eteplirsen-decision\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sarepta soars as FDA requests Dystrophin data prior to Eteplirsen decision</a></h4><ul>\n<li>The FDA has requested Sarepta (NASDAQ:<a href=\"https://seekingalpha.com/symbol/SRPT\" title=\"Sarepta Therapeutics, Inc.\">SRPT</a>) \"provide dystrophin data, as measured by western blot, from biopsies already obtained from the ongoing confirmatory study of eteplirsen ((PROMOVI)), as part of its ongoing evaluation of the eteplirsen New Drug Application (NDA).\"</li>\n<li>Sarepta \"plans to submit data from thirteen patient biopsy samples, at baseline and Week 48, to the FDA over the coming weeks to facilitate a prompt decision on the NDA by the Agency.\"</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/SRPT\" title=\"Sarepta Therapeutics, Inc.\">SRPT</a><font color=\"green\"> +23.8%</font> after hours to $19.87. Shares jumped <a href=\"https://seekingalpha.com/news/3185452-sarepta-says-fda-will-complete-eteplirsen-nda-review-thursday-shares-17-percent-premarket\" target=\"_blank\">two weeks ago</a> after the FDA said it needs more time to finish its review of Sarepta's Eteplirsen NDA.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187503\" data-linked=\"Sarepta soars as FDA requests Dystrophin data prior to Eteplirsen decision\" data-tweet=\"$SRPT - Sarepta soars as FDA requests Dystrophin data prior to Eteplirsen decision https://seekingalpha.com/news/3187503-sarepta-soars-fda-requests-dystrophin-data-prior-to-eteplirsen-decision?source=tweet\" data-url=\"https://seekingalpha.com/news/3187503-sarepta-soars-fda-requests-dystrophin-data-prior-to-eteplirsen-decision\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>31&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187498\" data-ts=\"1465248996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/Z\" target=\"_blank\">Z</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187498-zillow-paying-130m-to-settle-news-corp-nar-litigation-shares-rise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Zillow paying $130M to settle News Corp./NAR litigation; shares rise</a></h4><ul>\n<li>Zillow (<a href=\"https://seekingalpha.com/symbol/Z\" title=\"Zillow Group, Inc.\">Z</a>, <a href=\"https://seekingalpha.com/symbol/ZG\" title=\"Zillow Group, Inc.\">ZG</a>) has settled a lawsuit filed by News Corp.-owned (<a href=\"https://seekingalpha.com/symbol/NWS\" title=\"News Corporation\">NWS</a>, <a href=\"https://seekingalpha.com/symbol/NWSA\" title=\"News Corporation\">NWSA</a>) Move Inc., the National Association of Realtors (NAR), and three related entities for $130M. The settlement doesn't contain any admission of wrongdoing. (<a href=\"https://www.sec.gov/Archives/edgar/data/1617640/000119312516614149/d208399d8k.htm\" target=\"_blank\">8-K filing</a>)</li>\n<li>Move had sued Zillow for trade secret theft over its hiring of two former Move execs - chief industry development officer Errol Samuelson and MLS partnerships VP Curt Beardsley - and had claimed $2B in damages. Zillow sold off last month after receiving <a href=\"https://seekingalpha.com/news/3184284-zillow-slumps-following-mixed-ruling-move-case\" target=\"_blank\">a mixed ruling</a> in the suit regarding allegations the hired execs destroyed evidence that could've helped Move's case.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/Z\" title=\"Zillow Group, Inc.\">Z</a> <font color=\"green\">+8.5%</font> after hours to $32.90. <a href=\"https://seekingalpha.com/symbol/ZG\" title=\"Zillow Group, Inc.\">ZG</a> <font color=\"green\">+4%</font> to $32.00. Legal costs related to the lawsuit have had <a href=\"https://seekingalpha.com/news/3178889-zillow-makes-6-month-highs-marketplace-improvement-boosts-sales\" target=\"_blank\">a big impact</a> on Zillow's bottom line.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187498\" data-linked=\"Zillow paying $130M to settle News Corp./NAR litigation; shares rise\" data-tweet=\"$Z $Z $ZG - Zillow paying $130M to settle News Corp./NAR litigation; shares rise https://seekingalpha.com/news/3187498-zillow-paying-130m-to-settle-news-corp-nar-litigation-shares-rise?source=tweet\" data-url=\"https://seekingalpha.com/news/3187498-zillow-paying-130m-to-settle-news-corp-nar-litigation-shares-rise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187497\" data-ts=\"1465248957\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187497-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/GRMN' title='Garmin Ltd.'>GRMN</a> <font color='green'>+12.4%</font>. <a href='https://seekingalpha.com/symbol/QUNR' title='Qunar Cayman Islands Limited'>QUNR</a> <font color='green'>+12.0%</font>. <a href='https://seekingalpha.com/symbol/UNFI' title='United Natural Foods, Inc.'>UNFI</a> <font color='green'>+10.4%</font>. <a href='https://seekingalpha.com/symbol/Z' title='Zillow Group, Inc.'>Z</a> <font color='green'>+4.5%</font>. DNAI <font color='green'>+3.9%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/ALXN' title='Alexion Pharmaceuticals, Inc.'>ALXN</a> <font color='red'>-10.3%</font>. <a href='https://seekingalpha.com/symbol/IBN' title='ICICI Bank Ltd.'>IBN</a> <font color='red'>-16.6%</font>. <a href='https://seekingalpha.com/symbol/ENVA' title='Enova International, Inc.'>ENVA</a> <font color='red'>-10.0%</font>. <a href='https://seekingalpha.com/symbol/ESI-OLD' title='ITT Educational Services Inc.'>ESI-OLD</a> <font color='red'>-8.2%</font>. <a href='https://seekingalpha.com/symbol/SIGM' title='Sigma Designs, Inc.'>SIGM</a> <font color='red'>-5.9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187497\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$GRMN $QUNR $UNFI - After Hours Gainers / Losers https://seekingalpha.com/news/3187497-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3187497-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:35 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187487\" data-ts=\"1465245871\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALXN\" target=\"_blank\">ALXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187487-alexions-soliris-flunks-late-stage-study-in-ultra-rare-type-of-myasthenia-gravis-shares-off-9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alexion&#39;s Soliris flunks late-stage study in ultra-rare type of myasthenia gravis; shares off 9% after hours</a></h4><ul>\n<li>A Phase 3 clinical trial, called <a href=\"https://clinicaltrials.gov/ct2/show/NCT01997229?term=eculizumab&amp;cond=refractory+generalized+myasthenia+gravis&amp;rank=1\" target=\"_blank\">REGAIN</a>, assessing Alexion Pharmaceuticals' (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ALXN\" title=\"Alexion Pharmaceuticals, Inc.\">ALXN</a>) Soliris (eculizumab) for the treatment of refractory generalized <a href=\"http://www.ninds.nih.gov/disorders/myasthenia_gravis/detail_myasthenia_gravis.htm\" target=\"_blank\">myasthenia gravis</a> (gMG), an ultra-rare subset of MG, <a href=\"http://www.businesswire.com/news/home/20160606006430/en/Alexion-Announces-Topline-Results-Phase-3-REGAIN\" target=\"_blank\">failed to achieve</a> its primary objective but did hit several secondary endpoints.</li>\n<li>The primary endpoint was a statistically significant change from baseline to week 26 compared to placebo in a patient-reported daily activity scale called MG-ADL (p=0.0698).</li>\n<li>Secondary endpoints that were met included the change from baseline in a physician-administered assessment of MG clinical severity called QMG, the proportion of patients achieving at least a three-point reduction in MG-ADL total score and the proportion of patients with at least a five-point reduction in QMG score, all versus placebo.</li>\n<li>The company will continue to analyze the data. Complete results will be presented during the Hot Topics session at the 14th International Congress on Neuromuscular Diseases in Toronto on July 7.</li>\n<li>Soliris is currently approved to treat paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.</li>\n<li>Shares are down <font color=\"red\">9%</font> after hours on robust volume.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187487\" data-linked=\"Alexion&#39;s Soliris flunks late-stage study in ultra-rare type of myasthenia gravis; shares off 9% after hours\" data-tweet=\"$ALXN - Alexion&#39;s Soliris flunks late-stage study in ultra-rare type of myasthenia gravis; shares off 9% after hours https://seekingalpha.com/news/3187487-alexions-soliris-flunks-late-stage-study-in-ultra-rare-type-of-myasthenia-gravis-shares-off-9?source=tweet\" data-url=\"https://seekingalpha.com/news/3187487-alexions-soliris-flunks-late-stage-study-in-ultra-rare-type-of-myasthenia-gravis-shares-off-9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187465\" data-ts=\"1465243447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKNG\" target=\"_blank\">BKNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187465-tripadvisor-gains-amid-priceline-m-speculation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TripAdvisor gains amid Priceline M&amp;A speculation</a></h4><ul>     <li>With Kayak, Travelocity, HomeAway, and Orbitz having all been acquired, a Priceline (PCLN) purchase of TripAdvisor (<a href=\"https://seekingalpha.com/symbol/TRIP\" title=\"TripAdvisor Inc.\">TRIP</a> <font color=\"green\">+4.9%</font>) could be the online travel industry's next big M&amp;A transaction, <a href=\"http://www.bloomberg.com/gadfly/articles/2016-06-06/priceline-should-consider-a-deal-for-tripadvisor\" target=\"_blank\">argue</a> Bloomberg's Tara Lachapelle and Rani Molla.</li>     <li>The authors highlight the recent stagnation of Priceline's shares, and the fact TripAdvisor is well off its highs. Some challenges to a deal: TripAdvisor currently sports a $10.4B market cap and has a somewhat lofty valuation (32x a 2017 EPS consensus of $2.26), and TripAdvisor's ties to John Malone's Liberty Interactive (which controls Priceline archrival Expedia) could get in the way.</li>     <li>Though still <font color=\"red\">down 17%</font> YTD, TripAdvisor rallied to its highest levels since January today. Volume (3.05M shares) was well above a 3-month daily average of 2.16M.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187465\" data-linked=\"TripAdvisor gains amid Priceline M&amp;A speculation\" data-tweet=\"$BKNG $BKNG $TRIP - TripAdvisor gains amid Priceline M&amp;A speculation https://seekingalpha.com/news/3187465-tripadvisor-gains-amid-priceline-m-speculation?source=tweet\" data-url=\"https://seekingalpha.com/news/3187465-tripadvisor-gains-amid-priceline-m-speculation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187461\" data-ts=\"1465242657\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187461-best-buy-lower-after-ceo-cuts-stake-significantly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy lower after CEO cuts stake significantly</a></h4><ul> <li>Best Buy (<a href=\"https://seekingalpha.com/symbol/BBY\" title=\"Best Buy Co.\">BBY</a> <font color=\"red\">-2.8%</font>) is lower after CEO Hubert Joly reduces his <a href=\"http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=0000764478&amp;owner=exclude&amp;count=40&amp;hidefilings=0\" target=\"_blank\">stake</a> by about 44% with a round of selling.</li> <li>Filings show Joly unloaded 398K shares at an average price of $32.24.</li> <li>A spokesperson for the retailer says Joly's sale is related to his goal to diversify his personal holdings.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3187461\" data-linked=\"Best Buy lower after CEO cuts stake significantly\" data-tweet=\"$BBY - Best Buy lower after CEO cuts stake significantly https://seekingalpha.com/news/3187461-best-buy-lower-after-ceo-cuts-stake-significantly?source=tweet\" data-url=\"https://seekingalpha.com/news/3187461-best-buy-lower-after-ceo-cuts-stake-significantly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187460\" data-ts=\"1465242640\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMG\" target=\"_blank\">AMG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187460-investors-give-affiliated-managers-deal-thumbs-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors give Affiliated Managers deal a thumbs up</a></h4><ul><li>Affiliated Managers Group (<a href='https://seekingalpha.com/symbol/AMG' title='Affiliated Managers Group'>AMG</a> <font color='green'>+2.6%</font>) earlier <a href=\"https://seekingalpha.com/news/3187323-affiliated-managers-group-makes-alternative-investments-purchase\" target=\"_blank\">announced the purchase</a> of interests in five alternative asset managers for $800M, and expects the deal to add $0.50-$0.80 to EPS next year</li><li>Looking at the five, <a href=\"http://blogs.barrons.com/focusonfunds/2016/06/06/investors-cheer-affiliated-managers-groups-extension-into-alts/?mod=BOL_hp_blog_fof\" target=\"_blank\">Jefferies' Daniel Fallon figures two</a> - Winton Capital Group ($34.5B in AUM) and Capula ($12.7B) in AUM - account for about 85% of the acquired AUM and economics.</li><li>He notes these are alternative managers, further insulating AMG from the headwinds of U.S. active equity activity (where outflows are the trend of late).</li></ul><div class=\"tiny-share-widget\" data-id=\"3187460\" data-linked=\"Investors give Affiliated Managers deal a thumbs up\" data-tweet=\"$AMG - Investors give Affiliated Managers deal a thumbs up https://seekingalpha.com/news/3187460-investors-give-affiliated-managers-deal-thumbs-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3187460-investors-give-affiliated-managers-deal-thumbs-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:50 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187462\" data-ts=\"1465241994\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WFT\" target=\"_blank\">WFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187462-weatherford-upgraded-barclays-oil-services-stocks-lifted\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weatherford upgraded at Barclays; oil services stocks lifted</a></h4><ul>     <li>Weatherford (<a href=\"https://seekingalpha.com/symbol/WFT\" title=\"Weatherford International Ltd.\">WFT</a> <font color=\"green\">+8.3%</font>) is <a href=\"http://blogs.barrons.com/stockstowatchtoday/2016/06/06/weatherford-international-and-the-bulls-have-it/\" target=\"_blank\">upgraded</a> to Overweight from Equal Weight with an $8 price target, raised from $7, at Barclays following last week's $1.1B convertible debt issue and the settling of the Zubair change order claim for $150M meaningfully shifted the narrative away from the balance  sheet, removing considerable downside risk.</li>     <li>\"With near-term liquidity issues resolved, shares of WFT should start to recapture substantial YTD underperformance as focus starts so shift towards potential recovery amid low expectations,\" Barclays writes.</li>\n<li>However, the firm says WFT remains challenged with a highly levered  balance sheet and a weaker operational position vs. the big three oil services companies, as it does not possess the scale in either North America or internationally to compete in  markets that are becoming increasingly integrated.</li>     <li>Oil service (<a href=\"https://seekingalpha.com/symbol/OIH\" title=\"VanEck Vectors Oil Services ETF\">OIH</a> <font color=\"green\">+6.2%</font>) peers also are posting strong gains: <a href=\"https://seekingalpha.com/symbol/SLB\" title=\"Schlumberger Limited\">SLB</a> <font color=\"green\">+4.5%</font>, <a href=\"https://seekingalpha.com/symbol/HAL\" title=\"Halliburton Company\">HAL</a> <font color=\"green\">+4.6%</font>, BHI <font color=\"green\">+6.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187462\" data-linked=\"Weatherford upgraded at Barclays; oil services stocks lifted\" data-tweet=\"$WFT $WFTIQ $OIH - Weatherford upgraded at Barclays; oil services stocks lifted https://seekingalpha.com/news/3187462-weatherford-upgraded-barclays-oil-services-stocks-lifted?source=tweet\" data-url=\"https://seekingalpha.com/news/3187462-weatherford-upgraded-barclays-oil-services-stocks-lifted\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187455\" data-ts=\"1465239627\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187455-technology-top-5-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 3:00 pm</a></h4><ul>     <li>\n<b>Gainers:</b> <a href=\"https://seekingalpha.com/symbol/CBR\" title=\"CIBER, Inc.\">CBR</a> <font color=\"green\">+30%</font>. <a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a> <font color=\"green\">+27%</font>. <a href=\"https://seekingalpha.com/symbol/ENPH\" title=\"Enphase Energy Inc.\">ENPH</a> <font color=\"green\">+14%</font>. <a href=\"https://seekingalpha.com/symbol/PTI\" title=\"Proteostasis Therapeutics\">PTI</a> <font color=\"green\">+13%</font>. <a href=\"https://seekingalpha.com/symbol/BITA\" title=\"Bitauto Holdings Limited\">BITA</a> <font color=\"green\">+12%</font>.</li>\n<li>\n<b>Losers:</b> <a href=\"https://seekingalpha.com/symbol/BOSC\" title=\"B.O.S. Better Online Solutions\">BOSC</a> <font color=\"red\">-13%</font>. <a href=\"https://seekingalpha.com/symbol/CUDA\" title=\"Barracuda Networks, Inc\">CUDA</a> <font color=\"red\">-9%</font>. <a href=\"https://seekingalpha.com/symbol/GIG\" title=\"GigPeak, Inc.\">GIG</a> <font color=\"red\">-8%</font>. <a href=\"https://seekingalpha.com/symbol/PNTR\" title=\"Pointer Telocation Ltd.\">PNTR</a> <font color=\"red\">-5%</font>. <a href=\"https://seekingalpha.com/symbol/SPCB\" title=\"SuperCom, Ltd.\">SPCB</a> <font color=\"red\">-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187455\" data-linked=\"Technology - Top 5 Gainers / Losers as of 3:00 pm\" data-tweet=\"$CBR $YGE $ENPH - Technology - Top 5 Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3187455-technology-top-5-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3187455-technology-top-5-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187450\" data-ts=\"1465238830\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OISHF\" target=\"_blank\">OISHF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187450-report-interoil-wins-support-for-oil-search-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: InterOil wins support for Oil Search deal</a></h4><ul>     <li>Oil Search's (<a href=\"https://seekingalpha.com/symbol/OISHF\" title=\"Oil Search Ltd.\">OTCPK:OISHF</a>) $2.2B takeover deal for InterOil (<a href=\"https://seekingalpha.com/symbol/IOC\" title=\"InterOil Corporation\">IOC</a> <font color=\"green\">+1.8%</font>) is said to be <a href=\"http://www.smh.com.au/business/interoil-wins-support-for-oil-search-deal-20160605-gpbxpe.html\" target=\"_blank\">increasingly confident</a> that it has sufficient investor backing for the deal to proceed following meetings with key U.S. investors in recent days.</li>     <li>Capital Group, which owns more than 11% of IOC shares, has given its backing to the buyout ahead of two critical shareholder votes on the transaction, according to the <em>Sydney Morning Herald</em>.</li>     <li>Former IOC boss Phil Mulacek <a href=\"https://seekingalpha.com/news/3186674-former-interoil-ceo-mulacek-takes-legal-action-defer-oil-search-deal\" target=\"_blank\">recently started legal action</a> to postpone shareholder meetings and is putting forward five directors not endorsed by the board, but proxy advisors ISS and Glass Lewis have recommended investors vote for IOC's director nominees and reject Mulacek's resolutions.</li>\n<li>Mulacek today has released a <a href=\"http://www.concernedinteroilshareholders.com/\" target=\"_blank\">presentation</a> claiming IOC shareholders \"will forego billions of dollars of value... if the Oil Search proposal proceeds as  currently structured.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187450\" data-linked=\"Report: InterOil wins support for Oil Search deal\" data-tweet=\"$OISHF $OISHF $IOC - Report: InterOil wins support for Oil Search deal https://seekingalpha.com/news/3187450-report-interoil-wins-support-for-oil-search-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3187450-report-interoil-wins-support-for-oil-search-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187445\" data-ts=\"1465236840\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GCI\" target=\"_blank\">GCI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187445-tribune-soars-gannett-reportedly-pushing-ahead-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tribune soars; Gannett reportedly pushing ahead with bid</a></h4><ul>\n<li>\n<a href=\"http://www.cnbc.com/2016/06/06/tribune-publishing-surges-gannett-not-ready-to-drop-bid-sources-say.html\" target=\"_blank\">CNBC reports</a>  Gannett (<a href=\"https://seekingalpha.com/symbol/GCI\" title=\"Gannett Co., Inc.\">GCI</a> <font color=\"green\">+0.9%</font>) isn't ready to drop its $15/share bid for Tribune Publishing (TPUB <font color=\"green\">+13.4%</font>). In spite of today's big gains, Tribune still trades nearly $2.50 below  Gannett's offer price.</li>\n<li>The report comes after after ~41% of Tribune shareholders <a href=\"http://www.wsj.com/articles/tribune-vote-totals-show-40-withheld-their-board-votes-1465220646\" target=\"_blank\">withheld board votes</a> for both CEO Justin Dearborn and chairman Michael Ferro, Jr. at the company's annual meeting.</li>\n<li>Gannett had urged Tribune shareholders to withhold votes as a sign of protest to Tribune's rejection of Gannett's buyout offer. <a href=\"https://seekingalpha.com/news/3187000-gannett-tribune-board-vote-many-shareholders-backed-us\" target=\"_blank\">Gannett says</a> it believes 49% of Tribunes shares unaffiliated with the company were withheld, with over 50% withheld for Dearborn and Ferro.</li>\n<li>\n<a href=\"https://seekingalpha.com/news/3187045-tribune-publishing-becoming-tronc-moving-nasdaq\" target=\"_blank\">Four days ago:</a> Tribune changing name to Tronc, moving to Nasdaq</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187445\" data-linked=\"Tribune soars; Gannett reportedly pushing ahead with bid\" data-tweet=\"$GCI $GCI $TPCO - Tribune soars; Gannett reportedly pushing ahead with bid https://seekingalpha.com/news/3187445-tribune-soars-gannett-reportedly-pushing-ahead-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3187445-tribune-soars-gannett-reportedly-pushing-ahead-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:14 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187442\" data-ts=\"1465235515\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187442-solarcity-surges-after-credit-suisse-talks-up-solar-loans\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SolarCity surges after Credit Suisse talks up solar loans</a></h4><ul>     <li>Four days after SolarCity (SCTY <font color=\"green\">+8.4%</font>) <a href=\"https://seekingalpha.com/news/3186961-solarcity-revamps-solar-loan-offerings-amid-installation-growth-slowdown\" target=\"_blank\">officially announced</a> a revamp of its solar loan offering, Credit Suisse's Patrick Jobin asserts \"<a href=\"http://www.streetinsider.com/Analyst+Comments/SolarCity+%28SCTY%29+Gains+as+Analysts+Sing+Praises+of+New+Loan+Program/11712107.html\" target=\"_blank\">there are genuine advantages</a> to both homeowners and the residential solar development companies\" in a shift from solar leases/power purchase agreements (PPAs) to loans, even if \"ultimate value creation could be half the potential value realized under the leasing model.\"</li>     <li>Jobin: \"We calculate that for a typical customer in California, first year utility bill savings can be ~$261 for a solar PPA and slightly better with $272/yr savings with the loan, but with the loan becoming more advantaged over time as payments are fixed (not escalating) for 20 years. With the potential for 30% more realized savings than from a solar lease by year 5, coupled with the simple proposition that the consumer will own the system free &amp; clear after 10 or 20 years and generate 'free' power, we expect the transition to loans will continue.\"</li>     <li>Also: Deutsche's Vishal Shah issued yet another bullish SolarCity note late on Friday, stating talks with management left him \"incrementally more confident that SCTY remains on track to achieve its cost and cash flow break even target set for the year end.\" He added initial feedback for SolarCity's new loan offering \"has been very positive,\" and that the company \"is making good progress in securing financing required to achieve 2016 installation targets.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187442\" data-linked=\"SolarCity surges after Credit Suisse talks up solar loans\" data-tweet=\"$TSLA - SolarCity surges after Credit Suisse talks up solar loans https://seekingalpha.com/news/3187442-solarcity-surges-after-credit-suisse-talks-up-solar-loans?source=tweet\" data-url=\"https://seekingalpha.com/news/3187442-solarcity-surges-after-credit-suisse-talks-up-solar-loans\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187433\" data-ts=\"1465232447\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187433-financials-top-5-gainers-losers-of-1-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:00 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corp'>AAMC</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/VRTB-OLD' title='Vestin Realty Mortgage II, Inc.'>VRTB</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/SOHO' title='Sotherly Hotels Inc.'>SOHO</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/AEL' title='American Equity Investment Life Holding Company'>AEL</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/YRD' title='Yirendai LTD.'>YRD</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/AIII' title='ACRE Realty Investors Inc.'>AIII</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3187433\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:00 PM\" data-tweet=\"$AAMC $VRTB-OLD $MSB - Financials - Top 5 Gainers / Losers as of 1:00 PM https://seekingalpha.com/news/3187433-financials-top-5-gainers-losers-of-1-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3187433-financials-top-5-gainers-losers-of-1-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187430\" data-ts=\"1465231730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187430-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+453%</font>. <a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='green'>+86%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+63%</font>. <a href='https://seekingalpha.com/symbol/MOC' title='Command Security Corporation'>MOC</a> <font color='green'>+35%</font>. <a href='https://seekingalpha.com/symbol/YGE' title='Yingli Green Energy Holding Company Limited'>YGE</a> <font color='green'>+25%</font>. ARGS <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/CETX' title='Cemtrex, Inc.'>CETX</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/AAMC' title='Altisource Asset Management Corp'>AAMC</a> <font color='green'>+20%</font>. <a href='https://seekingalpha.com/symbol/CBR' title='CIBER, Inc.'>CBR</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+16%</font>.</li><li><b>Losers:</b> DNAI <font color='red'>-65%</font>. <a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='red'>-53%</font>. <a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color='red'>-43%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/BOSC' title='B.O.S. Better Online Solutions'>BOSC</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/TRIL' title='Trillium Therapeutics Inc.'>TRIL</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a> <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/SSL' title='Sasol Limited'>SSL</a> <font color='red'>-11%</font>. EBIO <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/CUDA' title='Barracuda Networks, Inc'>CUDA</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187430\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$HMNY $VBLT $CYCC - Midday Gainers / Losers https://seekingalpha.com/news/3187430-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3187430-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:48 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187428\" data-ts=\"1465231190\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GFI\" target=\"_blank\">GFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187428-gold-fields-considers-buying-anglogold-s-iduapriem-mine-in-ghana\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gold Fields considers buying AngloGold\u2019s Iduapriem mine in Ghana</a></h4><ul>     <li>Gold Fields (<a href=\"https://seekingalpha.com/symbol/GFI\" title=\"Gold Fields Limited\">GFI</a> <font color=\"red\">-3.5%</font>) says it is <a href=\"http://www.bloomberg.com/news/articles/2016-06-06/gold-fields-mulls-buying-anglogold-s-iduapriem-mine-in-ghana\" target=\"_blank\">interested in buying</a> AngloGold Ashanti\u2019s (<a href=\"https://seekingalpha.com/symbol/AU\" title=\"AngloGold Ashanti Limited\">AU</a> <font color=\"red\">-1.5%</font>) Iduapriem mine in Ghana, as it seeks to increase production from west Africa by about two-thirds to 1M oz.</li>     <li>GFI's VP for West Africa says the company is interested in the mine because of its proximity to its Tarkwa mine in southern Ghana; Tarkwa is the bigger of the two mines, producing 140K oz. during Q1 vs. Iduapriem\u2019s 46K oz.</li>     <li>The GFI exec says the company also is looking for opportunities to buy mines in Mali, Burkina Faso and Senegal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187428\" data-linked=\"Gold Fields considers buying AngloGold\u2019s Iduapriem mine in Ghana\" data-tweet=\"$GFI $GFI $AU - Gold Fields considers buying AngloGold\u2019s Iduapriem mine in Ghana https://seekingalpha.com/news/3187428-gold-fields-considers-buying-anglogold-s-iduapriem-mine-in-ghana?source=tweet\" data-url=\"https://seekingalpha.com/news/3187428-gold-fields-considers-buying-anglogold-s-iduapriem-mine-in-ghana\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187435\" data-ts=\"1465230085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSL\" target=\"_blank\">SSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187435-sasol-sinks-on-lower-earnings-hikes-cost-estimate-for-u-s-chemicals-complex\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sasol sinks on lower earnings; hikes cost estimate for U.S. chemicals complex</a></h4><ul>     <li>Sasol (<a href=\"https://seekingalpha.com/symbol/SSL\" title=\"Sasol Limited\">SSL</a> <font color=\"red\">-11.2%</font>) slides after saying profit in its fiscal year through June will <a href=\"http://www.bloomberg.com/news/articles/2016-06-06/sasol-profit-to-drop-on-760-million-charges-lower-oil-price\" target=\"_blank\">fall by as much as 30%</a> following writedowns.</li>     <li>SSL, which already impaired its stake in the Montney shale-gas properties in Canada by 7.4B rand in December, says it will recognize an additional writedown of ~4.1B rand because of lower natural gas prices.</li>     <li>SSL also <a href=\"http://www.miningweekly.com/article/sasol-revises-cost-of-louisiana-project-upwards-to-11bn-2016-06-06\" target=\"_blank\">raises the projected cost</a> of its chemicals complex in Lake Charles, La., to as much as $11B from a previous ~$8.9B amid construction delays.</li>     <li>SSL reduces expected returns from the chemicals project, which will convert ethane into plastics and other products, to around its weighted average cost of capital, which stands at ~10.6%.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187435\" data-linked=\"Sasol sinks on lower earnings; hikes cost estimate for U.S. chemicals complex\" data-tweet=\"$SSL - Sasol sinks on lower earnings; hikes cost estimate for U.S. chemicals complex https://seekingalpha.com/news/3187435-sasol-sinks-on-lower-earnings-hikes-cost-estimate-for-u-s-chemicals-complex?source=tweet\" data-url=\"https://seekingalpha.com/news/3187435-sasol-sinks-on-lower-earnings-hikes-cost-estimate-for-u-s-chemicals-complex\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:21 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187422\" data-ts=\"1465229402\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAV\" target=\"_blank\">NAV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187422-navistar-on-move-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Navistar on the move ahead of earnings</a></h4><ul> <li>Truck maker stocks are ahead of broad market averages with Navistar leading the way. Navistar (<a href=\"https://seekingalpha.com/symbol/NAV\" title=\"Navistar International Corporation\">NAV</a> <font color=\"green\">+6.6%</font>) is due to release earnings tomorrow with analysts expecting revenue of $2.239B and EPS of -$0.17 to be reported.</li> <li>Late last week, FTR issued a <a href=\"http://www.ftrintel.com/news/ftr-reports-preliminary-may-class-8-orders-stabilized-near-april-low-level\" target=\"_blank\">report</a> indicating that North American Class 8 truck orders improved 0.4% M/M to 14,100 units.</li> <li>The level of orders were still down 30% on a year-over-year comparison.</li> <li>\"Fleets do not need to order many trucks in the current environment because in most cases they have enough trucks to handle the freight.  Freight demand is still sluggish due to the build-up of business inventories,\" said a FTR commercial vehicles VP.</li> <li>Cummins (<a href=\"https://seekingalpha.com/symbol/CMI\" title=\"Cummins Inc.\">CMI</a> <font color=\"green\">+1.4%</font>) and PACCAR (<a href=\"https://seekingalpha.com/symbol/PCAR\" title=\"PACCAR Inc.\">PCAR</a> <font color=\"green\">+1.3%</font>) are both higher on the day.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187422\" data-linked=\"Navistar on the move ahead of earnings\" data-tweet=\"$NAV $NAV $CMI - Navistar on the move ahead of earnings https://seekingalpha.com/news/3187422-navistar-on-move-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3187422-navistar-on-move-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187420\" data-ts=\"1465228832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187420-consumer-goods-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer Goods - Top Gainers / Losers as of 12:00 pm</a></h4><ul>    <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/CVGW' title='Calavo Growers, Inc.'>CVGW</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/RDEN' title='Elizabeth Arden, Inc.'>RDEN</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/NAV' title='Navistar International Corporation'>NAV</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3187420\" data-linked=\"Consumer Goods - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$CVGW $RDEN $NAV - Consumer Goods - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3187420-consumer-goods-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3187420-consumer-goods-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187421\" data-ts=\"1465228721\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUE\" target=\"_blank\">NUE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187421-lew-blames-chinas-excess-steel-capacity-for-global-market-distortions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lew blames China&#39;s excess steel capacity for global market distortions</a></h4><ul>     <li>Steel stocks (<a href=\"https://seekingalpha.com/symbol/SLX\" title=\"VanEck Vectors Steel ETF\">SLX</a> <font color=\"green\">+2.1%</font>) are higher as U.S. Treasury Secretary Lew <a href=\"http://www.benzinga.com/news/16/06/8072720/u-s-treasury-secretary-blames-excess-steel-capacity-for-global-markets-distortion\" target=\"_blank\">blames China</a> for flooding low-cost steel into the U.S. and other markets.</li>     <li>Lew is urging China to cut excess steel production, as the two countries open high-level talks overshadowed by tension over the South China Sea.</li>     <li>\"The Chinese government is... engaged in <a href=\"http://blogs.wsj.com/economics/2016/06/06/why-the-u-s-steel-industry-is-molten-hot-over-chinas-trade-practices\" target=\"_blank\">economic warfare against the U.S.</a> and sadly, they are winning,\u201d Nucor (<a href=\"https://seekingalpha.com/symbol/NUE\" title=\"Nucor Corporation\">NUE</a> <font color=\"green\">+0.3%</font>) CEO John Ferriola says in a <em>WSJ</em> interview, adding that China two months ago set a new production record after spending two years promising to cut production.</li>     <li>Steel producers are mostly higher: <a href=\"https://seekingalpha.com/symbol/X\" title=\"United States Steel Corporation\">X</a> <font color=\"green\">+2.9%</font>, <a href=\"https://seekingalpha.com/symbol/MT\" title=\"ArcelorMittal\">MT</a> <font color=\"green\">+2.1%</font>, <a href=\"https://seekingalpha.com/symbol/CLF\" title=\"Cleveland-Cliffs, Inc.\">CLF</a> <font color=\"green\">+2.8%</font>, <a href=\"https://seekingalpha.com/symbol/AKS\" title=\"AK Steel Holding Corp\">AKS</a> <font color=\"red\">-1%</font>, <a href=\"https://seekingalpha.com/symbol/STLD\" title=\"Steel Dynamics, Inc.\">STLD</a> <font color=\"green\">+0.3%</font>, <a href=\"https://seekingalpha.com/symbol/RS\" title=\"Reliance Steel &amp; Aluminum Co.\">RS</a> <font color=\"green\">+0.4%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187421\" data-linked=\"Lew blames China&#39;s excess steel capacity for global market distortions\" data-tweet=\"$NUE $SLX $NUE - Lew blames China&#39;s excess steel capacity for global market distortions https://seekingalpha.com/news/3187421-lew-blames-chinas-excess-steel-capacity-for-global-market-distortions?source=tweet\" data-url=\"https://seekingalpha.com/news/3187421-lew-blames-chinas-excess-steel-capacity-for-global-market-distortions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187409\" data-ts=\"1465228567\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYCC\" target=\"_blank\">CYCC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187409-cyclacels-lead-product-candidates-show-encouraging-results-in-early-stage-study-in-treatment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cyclacel&#39;s lead product candidates show encouraging results in early-stage study in treatment-resistant cancers; shares up 66%</a></h4><ul>\n<li>Ultra-thinly traded Cyclacel Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/CYCC\" title=\"Cyclacel Pharmaceuticals, Inc.\">CYCC</a> <font color=\"green\">+66.3%</font>) heads north on a whopping 170x surge in volume, albeit on turnover of ~2.1M shares, in response to its <a href=\"http://investor.cyclacel.com/releasedetail.cfm?ReleaseID=974448\" target=\"_blank\">announcement</a> of data from a Phase 1 clinical trial assessing sapacitabine and seliciclib in heavily pretreated patients with advanced solid tumors. The results were presented today at ASCO16 in Chicago.</li>\n<li>Sapacitabine, currently in Phase 3 development in acute myeloid leukemia, is an oral nucleoside analogue prodrug whose metabolite, CNDAC, arrests the cell cycle by breaking up DNA. Orally available seliciclib, currently in Phase 2 for myelodysplastic syndrome , inhibits the enzymes CDK2 and CDK9, which play key roles in cell growth, survival and cell cycle control.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187409\" data-linked=\"Cyclacel&#39;s lead product candidates show encouraging results in early-stage study in treatment-resistant cancers; shares up 66%\" data-tweet=\"$CYCC - Cyclacel&#39;s lead product candidates show encouraging results in early-stage study in treatment-resistant cancers; shares up 66% https://seekingalpha.com/news/3187409-cyclacels-lead-product-candidates-show-encouraging-results-in-early-stage-study-in-treatment?source=tweet\" data-url=\"https://seekingalpha.com/news/3187409-cyclacels-lead-product-candidates-show-encouraging-results-in-early-stage-study-in-treatment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187417\" data-ts=\"1465228010\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLR\" target=\"_blank\">CLR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187417-continental-resources-rated-neutral-credit-suisse-after-shares-double\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Continental Resources rated Neutral at Credit Suisse after shares double</a></h4><ul>     <li>Continental Resources (<a href=\"https://seekingalpha.com/symbol/CLR\" title=\"Continental Resources, Inc.\">CLR</a> <font color=\"green\">+1.7%</font>) is higher after Credit Suisse initiates coverage with a <a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/16/06/8073554/continental-resources-an-oil-beta-play-credit-suisse-ini\" target=\"_blank\">Neutral rating</a> and $43 price target after the stock more than doubles off YTD lows.</li>     <li>However, the firm says CLR's large acreage positions in the Bakken, STACK and SCOOP \"offer captured resource development opportunities as commodity prices increase\"; the STACK has been among the best improvers among shale, with higher oil cuts, flow rates and encouraging spacing tests, and CLR has low breakeven inventory in the Springer and core Bakken.</li>     <li>CLR \u201chas demonstrated strong operational credentials in shale and offers investors oil beta given the relatively high share of oil in production (66%),\u201d Credit Suisse says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187417\" data-linked=\"Continental Resources rated Neutral at Credit Suisse after shares double\" data-tweet=\"$CLR - Continental Resources rated Neutral at Credit Suisse after shares double https://seekingalpha.com/news/3187417-continental-resources-rated-neutral-credit-suisse-after-shares-double?source=tweet\" data-url=\"https://seekingalpha.com/news/3187417-continental-resources-rated-neutral-credit-suisse-after-shares-double\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187411\" data-ts=\"1465226861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIM\" target=\"_blank\">CIM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187411-chimera-gets-price-target-boost-nomura\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chimera gets price target boost at Nomura</a></h4><ul>\n<li>\"Due to its distinctive business model and predominantly credit rather than rate sensitivity, Chimera (<a href=\"https://seekingalpha.com/symbol/CIM\" title=\"Chimera Investment Corporation\">CIM</a> <font color=\"green\">+1.1%</font>) is well positioned for a wide range of economic outcomes,\" says Nomura, <a href=\"https://www.thestreet.com/story/13597148/1/chimera-investment-cim-stock-price-target-raised-at-nomura.html?puc=yahoo&amp;cm_ven=YAHOO\" target=\"_blank\">lifting the price target </a>on the Buy-rated stock to $17 from $16 (current price is $15.36).</li>\n<li>Chimera, says the team, offers a mid-teen ROE, and a bank-line net interest spread without the burdens of bank-like regulation.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187411\" data-linked=\"Chimera gets price target boost at Nomura\" data-tweet=\"$CIM - Chimera gets price target boost at Nomura https://seekingalpha.com/news/3187411-chimera-gets-price-target-boost-nomura?source=tweet\" data-url=\"https://seekingalpha.com/news/3187411-chimera-gets-price-target-boost-nomura\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187406\" data-ts=\"1465226168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRKR\" target=\"_blank\">PRKR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187406-parkervision-gains-after-suing-lg-in-germany\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ParkerVision gains after suing LG in Germany</a></h4><ul>\n<li>ParkerVision (<a href=\"https://seekingalpha.com/symbol/PRKR\" title=\"ParkerVision, Inc.\">OTC:PRKR</a> <font color=\"green\">+8.3%</font>) is suing LG Electronics' German subsidiary, alleging LG smartphones infringe the company's '831 European patent.</li>\n<li>The move comes six months after <a href=\"https://seekingalpha.com/news/2985986-parkervision-sues-apple-samsung-others-itc-complaint\" target=\"_blank\">ParkerVision sued</a> Apple, Samsung, LG, and Qualcomm for allegedly infringing four patents. The ITC is reviewing the complaint.</li>\n<li>Also: SA contributor Don Dion <a href=\"https://seekingalpha.com/article/3980105-excellent-time-pick-parkervision\" target=\"_blank\">made a bull case</a> for ParkerVision in an article today in which he highlighted the funding ParkerVision has received from money manager Juridica Asset Management.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187406\" data-linked=\"ParkerVision gains after suing LG in Germany\" data-tweet=\"$PRKR - ParkerVision gains after suing LG in Germany https://seekingalpha.com/news/3187406-parkervision-gains-after-suing-lg-in-germany?source=tweet\" data-url=\"https://seekingalpha.com/news/3187406-parkervision-gains-after-suing-lg-in-germany\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187405\" data-ts=\"1465225803\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRTX\" target=\"_blank\">MRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187405-side-effects-excessive-in-early-stage-study-of-miratis-lead-product-candidate-new-formulation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Side effects excessive in early-stage study of Mirati&#39;s lead product candidate, new formulation being implemented in Phase 2; shares off 40%</a></h4><ul>\n<li>Thinly traded micro cap Mirati Therapeutics (<a href=\"https://seekingalpha.com/symbol/MRTX\" title=\"Mirati Therapeutics, Inc.\">MRTX</a> <font color=\"red\">-40.1%</font>) plummets in early trading on a 6x surge in volume in response to its update on its clinical trials. The company reported results from a Phase 1b study evaluating lead product <a href=\"http://www.mirati.com/programs/mgcd265/\" target=\"_blank\">glesatinib</a>, a tyrosine kinase inhibitor that selectively targets certain genetic profiles of lung cancer patients called MET and Axl, in 22 subjects with non-small cell lung cancer (NSCLC).</li>\n<li>11 of the 22 participants had genetic driver alterations similar to the selection criteria for the company's ongoing Phase 2 study. Tumor regression was observed in 10 of the 11 (90.9%), but only three (27.3%) were partial responders pre RECIST criteria.</li>\n<li>Side effects appeared to be a problem, however. Nine of the 11 subjects (81.8%) experienced dose reductions and or dose interruptions. Four of the nine experienced one reduction, two had two reductions and three had multiple reductions while on study. Eight of the subjects are no longer on trial: five discontinued due to disease progression, two related to adverse events and one withdrew consent. The dose reductions were due primarily to episodes of diarrhea. According to the company, the likely culprit was the presence of a castor oil-like ingredient in glesatinib's formulation called miglyol.</li>\n<li>To address the problem, a new spray-dried dispersion formulation of glesatinib is being implemented in the <a href=\"https://clinicaltrials.gov/ct2/show/NCT02544633?term=mgcd265&amp;rank=2\" target=\"_blank\">Phase 2 study</a>. One partial responder who moved to the new formulation has shown an improved response and remains on study but at a dose of 500 mg twice daily, lower that the established dose of 750 mg twice daily. According to clinicaltrials.gov, the estimated final data collection date for the primary endpoint is July 2017. The estimated study completion date is July 2018.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187405\" data-linked=\"Side effects excessive in early-stage study of Mirati&#39;s lead product candidate, new formulation being implemented in Phase 2; shares off 40%\" data-tweet=\"$MRTX - Side effects excessive in early-stage study of Mirati&#39;s lead product candidate, new formulation being implemented in Phase 2; shares off 40% https://seekingalpha.com/news/3187405-side-effects-excessive-in-early-stage-study-of-miratis-lead-product-candidate-new-formulation?source=tweet\" data-url=\"https://seekingalpha.com/news/3187405-side-effects-excessive-in-early-stage-study-of-miratis-lead-product-candidate-new-formulation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187380\" data-ts=\"1465225281\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187380-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VBLT' title='VBL Therapeutics'>VBLT</a> <font color='green'>+81%</font>. <a href='https://seekingalpha.com/symbol/CYCC' title='Cyclacel Pharmaceuticals, Inc.'>CYCC</a> <font color='green'>+64%</font>. ARGS <font color='green'>+13%</font>. ONTY <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ONTX' title='Onconova Therapeutics'>ONTX</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> DNAI <font color='red'>-65%</font>. <a href='https://seekingalpha.com/symbol/ADMP' title='Adamis Pharmaceuticals Corp.'>ADMP</a> <font color='red'>-52%</font>. <a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a> <font color='red'>-42%</font>. <a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/CRBP' title='Corbus Pharmaceuticals Holdings, Inc.'>CRBP</a> <font color='red'>-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3187380\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$VBLT $CYCC $ARGSQ - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3187380-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3187380-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187395\" data-ts=\"1465223575\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASPS\" target=\"_blank\">ASPS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187395-day-two-of-gains-for-altisource-portfolio-after-raised-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Day two of gains for Altisource Portfolio after raised estimates</a></h4><ul>\n<li>Compass Point's Fred Small on Friday raised his EPS estimate for Q2 to $1.90 from $1.63, and for Q3 to $1.89 from $1.61.</li>\n<li>For full year 2016, Small now sees EPS of $6.66 vs. $5.55 previously - this for a $27.50 stock (the price when the estimates were lifted; it's up to $30.51 currently). In 2017, Small expects EPS of $5.95 vs. $5.62 previously.</li>\n<li>\n<a href=\"https://seekingalpha.com/symbol/ASPS\" title=\"Altisource Portfolio Solutions SA\">ASPS</a> <font color=\"green\">+5.2%</font> in today's session.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187395\" data-linked=\"Day two of gains for Altisource Portfolio after raised estimates\" data-tweet=\"$ASPS - Day two of gains for Altisource Portfolio after raised estimates https://seekingalpha.com/news/3187395-day-two-of-gains-for-altisource-portfolio-after-raised-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3187395-day-two-of-gains-for-altisource-portfolio-after-raised-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187388\" data-ts=\"1465222045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIDU\" target=\"_blank\">BIDU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187388-baidu-tencent-jd-com-and-investment-firm-pour-300m-bitauto\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baidu, Tencent, JD.com, and investment firm pour $300M into Bitauto</a></h4><ul>\n<li>Search giant Baidu (<a href=\"https://seekingalpha.com/symbol/BIDU\" title=\"Baidu, Inc.\">BIDU</a> <font color=\"green\">+1%</font>), messaging/gaming giant Tencent (<a href=\"https://seekingalpha.com/symbol/TCEHY\" title=\"Tencent Holding Ltd. ADR\">OTCPK:TCEHY</a>), and #2 Chinese e-commerce firm JD.com (<a href=\"https://seekingalpha.com/symbol/JD\" title=\"JD.com\">JD</a> <font color=\"green\">+1.8%</font>) are each investing $50M in leading Chinese online auto platform Bitauto (<a href=\"https://seekingalpha.com/symbol/BITA\" title=\"Bitauto Holdings Limited\">BITA</a> <font color=\"green\">+12%</font>). Bitauto is also selling $150M worth of convertible bonds to investment firm PAG.</li>\n<li>Baidu, Tencent, and JD are each buying 2.47M Bitauto shares at $20.23 apiece ($0.23 below Friday's close). The deal follows JD and Tencent's <a href=\"https://seekingalpha.com/news/2214955-jd-com-tencent-investing-1_55b-in-bitauto\" target=\"_blank\">$1.55B 2015 investment</a> in the company, and respectively leaves JD, Tencent, and Baidu holding 23.5%, 7.1%, and 3.2% stakes.</li>\n<li>The bonds are due five years from issuance, and carry a 2% interest rate and $23.67/share conversion price. Owners of the convertible debt will hold an 8.2% stake. Bitauto chairman/CEO William Li will be buying a portion of the debt through PAG, by means of a total return swap agreement.</li>\n<li>Bitauto is up sharply. Rival Autohome (<a href=\"https://seekingalpha.com/symbol/ATHM\" title=\"Autohome Inc.\">ATHM</a> <font color=\"green\">+3.2%</font>) is posting moderate gains. Li: \"Through our new partnership with Baidu, we expect to leverage its leadership in mobile and desktop online search, big data and transaction services platforms for additional strategic advantages as we continue to create the industry leading new and used car purchasing experience for customers in China.\"</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187388\" data-linked=\"Baidu, Tencent, JD.com, and investment firm pour $300M into Bitauto\" data-tweet=\"$BIDU $BIDU $TCEHY - Baidu, Tencent, JD.com, and investment firm pour $300M into Bitauto https://seekingalpha.com/news/3187388-baidu-tencent-jd-com-and-investment-firm-pour-300m-bitauto?source=tweet\" data-url=\"https://seekingalpha.com/news/3187388-baidu-tencent-jd-com-and-investment-firm-pour-300m-bitauto\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187386\" data-ts=\"1465221857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSN\" target=\"_blank\">TSN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187386-meat-stocks-slump-after-bmo-capital-warns-on-valuation\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Meat stocks slump after BMO Capital warns on valuation</a></h4><ul> <li>BMO Capital takes a dimmer view on the upside for meat producers after factoring in the strong rally in the sector which has pushed up valuation levels.</li> <li>Tyson Foods (<a href=\"https://seekingalpha.com/symbol/TSN\" title=\"Tyson Foods Inc.\">TSN</a> <font color=\"red\">-3.4%</font>) and Pilgrim's Pride (<a href=\"https://seekingalpha.com/symbol/PPC\" title=\"Pilgrim's Pride Corporation\">PPC</a> <font color=\"red\">-3%</font>) are both moved by BMO to Market Perform from Outperform.</li> <li>BMO <a href=\"http://www.marketbeat.com/stocks/NYSE/TSN/\" target=\"_blank\">set</a> a price target of $69 on TSN and PPC caught a $27 PT.</li> <li>It's a weak day across the sector with Sanderson Farms (<a href=\"https://seekingalpha.com/symbol/SAFM\" title=\"Sanderson Farms, Inc.\">SAFM</a> <font color=\"red\">-1.9%</font>), Hormel (<a href=\"https://seekingalpha.com/symbol/HRL\" title=\"Hormel Foods Corporation\">HRL</a> <font color=\"red\">-0.7%</font>) and JBS (<a href=\"https://seekingalpha.com/symbol/JBSAY\" title=\"JBS S.A. ADR\">OTCQX:JBSAY</a> <font color=\"red\">-2.3%</font>) ADRs all lower.</li>\n<li>Related sector news: <a href=\"https://seekingalpha.com/news/3187273-plant-based-hamburger-startup-creates-interesting-sizzle\" target=\"_blank\">Plant-based hamburger startup creates some interesting sizzle</a> (June 4)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187386\" data-linked=\"Meat stocks slump after BMO Capital warns on valuation\" data-tweet=\"$TSN $TSN $PPC - Meat stocks slump after BMO Capital warns on valuation https://seekingalpha.com/news/3187386-meat-stocks-slump-after-bmo-capital-warns-on-valuation?source=tweet\" data-url=\"https://seekingalpha.com/news/3187386-meat-stocks-slump-after-bmo-capital-warns-on-valuation\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187385\" data-ts=\"1465221560\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBR\" target=\"_blank\">PBR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187385-brazil-energy-ministry-says-supports-petrobras-fuel-pricing-independence\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil energy ministry says it supports Petrobras fuel-pricing independence</a></h4><ul>     <li>Brazil's energy ministry said on Saturday it <a href=\"http://www.reuters.com/article/brazil-petrobras-prices-idUSL1N18X00U\" target=\"_blank\">backed full independence</a> for Petrobras (<a href=\"https://seekingalpha.com/symbol/PBR\" title=\"Petrobras - Petroleo Brasileiro S.A.\">PBR</a> <font color=\"green\">+1.8%</font>) to set domestic fuel prices.</li>     <li>PBR and other state-controlled companies, such as  utility Eletrobras (NYSE:<a href=\"https://seekingalpha.com/symbol/EBR\" title=\"Centrais Eletricas Brasileiras S.A. - Eletrobras\">EBR</a>), with shares owned by non-government  investors should be free to act in their best interests without government interference, the ministry said in a  statement.</li>     <li>Fuel-price controls were adopted by the government to control inflation bound slashed PBR's revenue, helping cause debt to balloon to nearly $130B, and starved Brazil's biggest company of its ability to finance one of the world's largest-ever capital spending  plans.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187385\" data-linked=\"Brazil energy ministry says it supports Petrobras fuel-pricing independence\" data-tweet=\"$PBR $PBR $EBR - Brazil energy ministry says it supports Petrobras fuel-pricing independence https://seekingalpha.com/news/3187385-brazil-energy-ministry-says-supports-petrobras-fuel-pricing-independence?source=tweet\" data-url=\"https://seekingalpha.com/news/3187385-brazil-energy-ministry-says-supports-petrobras-fuel-pricing-independence\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187379\" data-ts=\"1465221085\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FIT\" target=\"_blank\">FIT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187379-fitbit-lower-on-cautious-analyst-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Fitbit lower on cautious analyst comments</a></h4><ul><li>Cleveland Research is reportedly lowering unit estimates for Fitbit (<a href='https://seekingalpha.com/symbol/FIT' title='Fitbit, Inc.'>FIT</a> <font color='red'>-1.9%</font>), saying the activity tracker market is \"increasingly saturated.\" This may be the first time anyone has lowered current fiscal year unit numbers for Fitbit, <a href=\"https://twitter.com/thenotablecalls/status/739812052559106048\" target=\"_blank\">says Notable Calls</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3187379\" data-linked=\"Fitbit lower on cautious analyst comments\" data-tweet=\"$FIT - Fitbit lower on cautious analyst comments https://seekingalpha.com/news/3187379-fitbit-lower-on-cautious-analyst-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3187379-fitbit-lower-on-cautious-analyst-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187376\" data-ts=\"1465220671\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IRET\" target=\"_blank\">IRET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187376-investors-real-estate-trust-to-become-pure-play-apartment-reit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors Real Estate Trust to become pure-play apartment REIT</a></h4><ul>\n<li>The company this morning announces its intention to dispose of all healthcare and industrial properties, allowing it to focus on its multifamily platform.</li>\n<li>Fans will remember the company at the start of 2015 initiating a plan to focus on core assets, and in the nine months ending on Jan. 31, 5.1M square feet of commercial real estate was sold.</li>\n<li>\n<a href=\"http://www.sec.gov/Archives/edgar/data/798359/000110465916125531/a16-12789_1ex99d2.htm\" target=\"_blank\">According to presentation slides</a> released alongside today's announcement, multifamily currently makes up 63% of <a href=\"https://seekingalpha.com/symbol/IRET\" title=\"Investors Real Estate Trust\">IRET</a>'s portfolio, up from 44.6% at the start of 2015. Healthcare is 31%, and industrial 3.4%. Office and retail are each less than 2%.</li>\n<li>Shares <font color=\"green\">+1.25%</font>\n</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187376\" data-linked=\"Investors Real Estate Trust to become pure-play apartment REIT\" data-tweet=\"$IRET - Investors Real Estate Trust to become pure-play apartment REIT https://seekingalpha.com/news/3187376-investors-real-estate-trust-to-become-pure-play-apartment-reit?source=tweet\" data-url=\"https://seekingalpha.com/news/3187376-investors-real-estate-trust-to-become-pure-play-apartment-reit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187372\" data-ts=\"1465219434\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SRRA\" target=\"_blank\">SRRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187372-pronai-therapeutics-suspends-development-of-lead-dnai-candidate-on-tepid-results-in-mid-stage\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ProNAi Therapeutics suspends development of lead DNAi candidate on tepid results in mid-stage study; shares slump 54% premarket</a></h4><ul>\n<li>Thinly traded micro cap ProNAi Therapeutics (DNAI) slumps <font color=\"red\">54%</font> premarket on robust volume in response to its <a href=\"https://www.sec.gov/Archives/edgar/data/1290149/000119312516613238/d204669dex991.htm\" target=\"_blank\">announcement </a>that it has suspended development of its lead DNAi candidate, PNT2258, after interim results from a Phase 2 clinical trial in relapsed/refractory diffuse large B-cell lymphoma failed to show enough of a treatment effect to justify continuing. The response rate for the the first 37 patients treated with PNT2258 as a single agent was only 8.1%. The company is also stopping all further investment in the DNAi platform.</li>\n<li>\n<a href=\"http://pronai.com/pnt2258-targeting-bcl2/\" target=\"_blank\">PNT2258 </a>is also being evaluated in patients with <a href=\"https://en.wikipedia.org/wiki/Richter%27s_transformation\" target=\"_blank\">Richter's transformation</a>, an aggressive lymphoma with a poor prognosis, but no responses have been observed yet (four of the five subjects have dropped out of the study).</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187372\" data-linked=\"ProNAi Therapeutics suspends development of lead DNAi candidate on tepid results in mid-stage study; shares slump 54% premarket\" data-tweet=\"$SRRA - ProNAi Therapeutics suspends development of lead DNAi candidate on tepid results in mid-stage study; shares slump 54% premarket https://seekingalpha.com/news/3187372-pronai-therapeutics-suspends-development-of-lead-dnai-candidate-on-tepid-results-in-mid-stage?source=tweet\" data-url=\"https://seekingalpha.com/news/3187372-pronai-therapeutics-suspends-development-of-lead-dnai-candidate-on-tepid-results-in-mid-stage\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187370\" data-ts=\"1465218935\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187370-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul><li><b>Gainers:</b> ONTY <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/BPTH' title='Bio-Path Holdings, Inc.'>BPTH</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/ALQA' title='Alliqua BioMedical, Inc.'>ALQA</a> <font color='green'>+9%</font>.&nbsp;<a href='https://seekingalpha.com/symbol/CLDX' title='Celldex Therapeutics, Inc'>CLDX</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> DNAI <font color='red'>-53%</font>. <a href='https://seekingalpha.com/symbol/MRTX' title='Mirati Therapeutics, Inc.'>MRTX</a> <font color='red'>-32%</font>. <a href='https://seekingalpha.com/symbol/SSL' title='Sasol Limited'>SSL</a> <font color='red'>-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3187370\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$CASC $BPTH $ADYX - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3187370-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3187370-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187363\" data-ts=\"1465218285\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187363-ocular-therapeutixs-dextenza-flunks-late-stage-study-in-ocular-itching-associated-allergic\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix&#39;s Dextenza flunks late-stage study in ocular itching associated with allergic conjunctivitis; shares slump 42% premarket</a></h4><ul>\n<li>Thinly traded micro cap Ocular Therapeutix (NASDAQ:<a href=\"https://seekingalpha.com/symbol/OCUL\" title=\"Ocular Therapeutix\">OCUL</a>) is down <font color=\"red\">42%</font> premarket on increased volume in response to its announcement that its second Phase 3 clinical trial assessing lead product candidate DEXTENZA (sustained release dexamethasone) for the treatment of ocular itching associated with chronic allergic conjunctivitis failed to beat placebo.</li>\n<li>The primary endpoint was the difference in the mean scores in ocular itching at three time points seven days following insertion. The data favored DEXTENZA but fell short of statistical significance. The study also failed to achieve the requirement of at least a 0.5 unit difference at all three time points seven days following insertion and at least a 1.0 unit difference at the majority of the three time points between the DEXTENZA and placebo seven days following insertion.</li>\n<li>The first Phase 3 study was successful. The company plans to meet with the FDA to clarify a path forward for the indication. The company's NDA for the treatment of ocular pain following ophthalmic surgery is currently under review with an action date of July 24.</li>\n<li>\n<a href=\"http://www.ocutx.com/pipeline/dexamethasone-punctum-plug\" target=\"_blank\">DEXTENZA </a>is designed to deliver dexamethasone, a corticosteroid, to the ocular surface for four weeks. It is placed through the <a href=\"https://en.wikipedia.org/wiki/Punctum\" target=\"_blank\">punctum</a> (small opening), a natural opening in the eyelid, into the canaliculus (small channel in the eyelid) where it is resorbed over time.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/2851106-ocular-therapeutixs-dextenza-successful-late-stage-study-allergic-conjunctivitis\" target=\"_blank\">Ocular Therapeutix's DEXTENZA successful in late-stage study in allergic conjunctivitis</a> (Oct. 22, 2015)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187363\" data-linked=\"Ocular Therapeutix&#39;s Dextenza flunks late-stage study in ocular itching associated with allergic conjunctivitis; shares slump 42% premarket\" data-tweet=\"$OCUL - Ocular Therapeutix&#39;s Dextenza flunks late-stage study in ocular itching associated with allergic conjunctivitis; shares slump 42% premarket https://seekingalpha.com/news/3187363-ocular-therapeutixs-dextenza-flunks-late-stage-study-in-ocular-itching-associated-allergic?source=tweet\" data-url=\"https://seekingalpha.com/news/3187363-ocular-therapeutixs-dextenza-flunks-late-stage-study-in-ocular-itching-associated-allergic\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187359\" data-ts=\"1465218138\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMZN\" target=\"_blank\">AMZN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187359-whole-foods-market-on-watch-for-barrons-bounce\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Whole Foods Market on watch for Barron&#39;s bounce</a></h4><ul> <li>Shares of Whole Foods Market (WFM) after the grocery store stock was <a href=\"http://www.barrons.com/articles/whole-foods-healthy-gains-ahead-1465022636\" target=\"_blank\">profiled</a> favorably in Barron's over the weekend.</li> <li>The positive take on Whole Foods is based on the premise that the company can cut costs to help offset some of the lower merchandise margins. The introduction of the 365 chain is also seen as adding long-term value.</li> <li>New buyers could see a return of as much as 20% over the next year as Whole Foods get backs on track, reasons Barron's.</li> <li>WFM <font color=\"green\">+1.26%</font> premarket to $34.50.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187359\" data-linked=\"Whole Foods Market on watch for Barron&#39;s bounce\" data-tweet=\"$AMZN - Whole Foods Market on watch for Barron&#39;s bounce https://seekingalpha.com/news/3187359-whole-foods-market-on-watch-for-barrons-bounce?source=tweet\" data-url=\"https://seekingalpha.com/news/3187359-whole-foods-market-on-watch-for-barrons-bounce\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187350\" data-ts=\"1465216424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VBLT\" target=\"_blank\">VBLT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187350-study-shows-vascular-bios-lead-product-candidate-vbminus-111-significantly-increased-survival\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Study shows Vascular Bio&#39;s lead product candidate VB-111 significantly increased survival in treatment-resistant ovarian cancer; shares rise 33% premarket</a></h4><ul>\n<li>Thinly traded nano cap Vascular Biogenics (NASDAQ:<a href=\"https://seekingalpha.com/symbol/VBLT\" title=\"VBL Therapeutics\">VBLT</a>) is up <font color=\"green\">33%</font> premarket on robust volume in response to its <a href=\"http://ir.vblrx.com/phoenix.zhtml?c=253311&amp;p=irol-newsArticle&amp;ID=2175212\" target=\"_blank\">announcement </a>of positive results from a Phase 1/2 clinical trial assessing lead product candidate VB-111 in women with recurrent platinum-resistant ovarian cancer. The data were presented at today at ASCO16 in Chicago.</li>\n<li>Results showed patients treated with a therapeutic dose of VB-111 experienced median overall survival of 810 days compared to 172 days in the lose dose arm. The difference was statistically significant (p=0.042). There was also a doubling of the durable response rate to 60% (as measured by the biomarker CA-125) compared to historical rates for Roche's (<a href=\"https://seekingalpha.com/symbol/RHHBY\" title=\"Roche Holding Ltd ADR\">OTCQX:RHHBY</a>) <a href=\"http://www.avastin.com/patient\" target=\"_blank\">Avastin</a> (bevacizumab) plus chemo.</li>\n<li>VB-111 was safe and well-tolerated. Eight serious adverse events were reported, two potentially related to VB-111. No dose-limiting toxicities were observed at any dose level.</li>\n<li>The company plans to have an end-of-Phase 2 meeting with the FDA to review the data and clarify the next steps in the clinical development of VB-111.</li>\n<li>\n<a href=\"http://www.vblrx.com/cancer-programs/cancer-pipline/\" target=\"_blank\">VB-111</a> is an intravenously-administered next-generation anti-angiogenic agent that utilizes the company's <a href=\"http://www.vblrx.com/cancer-programs/cancer-platform/\" target=\"_blank\">Vascular Targeting System </a>to target endothelial cells in the tumor vasculature.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187350\" data-linked=\"Study shows Vascular Bio&#39;s lead product candidate VB-111 significantly increased survival in treatment-resistant ovarian cancer; shares rise 33% premarket\" data-tweet=\"$VBLT $VBLT $RHHBY - Study shows Vascular Bio&#39;s lead product candidate VB-111 significantly increased survival in treatment-resistant ovarian cancer; shares rise 33% premarket https://seekingalpha.com/news/3187350-study-shows-vascular-bios-lead-product-candidate-vbminus-111-significantly-increased-survival?source=tweet\" data-url=\"https://seekingalpha.com/news/3187350-study-shows-vascular-bios-lead-product-candidate-vbminus-111-significantly-increased-survival\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187348\" data-ts=\"1465216350\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YGE\" target=\"_blank\">YGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187348-yingli-green-energyplus-33-sees-first-positive-quarterly-net-income-since-2011\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Yingli Green Energy +33%, sees first positive quarterly net income since 2011</a></h4><ul>\n<li>Yingli Green Energy (NYSE:<a href=\"https://seekingalpha.com/symbol/YGE\" title=\"Yingli Green Energy Holding Company Limited\">YGE</a>) <font color=\"green\">+33.1%</font> premarket after saying it expects that its Q1 net income turned positive for the first time since Q3 2011, with an estimated net margin of 2.5%-4.5%.</li>\n<li>YGE says its Q1 PV module shipments likely totaled 500-510 MW, at the high end of its previous  guidance of 480-510 MW.</li>\n<li>YGE also estimates that its Q1 overall gross margin was in the 18.5%-20.5% range, a significant  Q/Q increase, primarily due to the  higher average selling price of its PV modules because of a higher proportion of  shipments to Japan, where the selling price generally is  higher than in other markets.</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187348\" data-linked=\"Yingli Green Energy +33%, sees first positive quarterly net income since 2011\" data-tweet=\"$YGE - Yingli Green Energy +33%, sees first positive quarterly net income since 2011 https://seekingalpha.com/news/3187348-yingli-green-energyplus-33-sees-first-positive-quarterly-net-income-since-2011?source=tweet\" data-url=\"https://seekingalpha.com/news/3187348-yingli-green-energyplus-33-sees-first-positive-quarterly-net-income-since-2011\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187330\" data-ts=\"1465214213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMP\" target=\"_blank\">ADMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187330-adamis-pharmas-nda-for-epinephrine-pre-filled-syringe-rejected-second-time-fda-shares-plummet\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Adamis Pharma&#39;s NDA for epinephrine pre-filled syringe rejected a second time by FDA; shares plummet 49% premarket</a></h4><ul>\n<li>Adamis Pharmaceuticals (NASDAQ:<a href=\"https://seekingalpha.com/symbol/ADMP\" title=\"Adamis Pharmaceuticals Corp.\">ADMP</a>) receives a Complete Response Letter (CRL) from the FDA in response to its New Drug Application (NDA) seeking approval of Epinephrine Injection USP 1:1000 0.3mg Pre-filled Single Dose Syringe (PFS) for the emergency treatment of a severe allergic reaction called acute anaphylaxis. The company also received a CRL in March 2015.</li>\n<li>The agency informed the company that it needs to expand its human factors study (patient usability) and reliability study (product stress testing). Adamis believes its can generate the data fairly quickly and resubmit the NDA in H2.</li>\n<li>The first CRL related to CMC (Chemistry, Manufacturing and Controls), specifically to the volume of dose delivered by the syringe, including the ability to deliver volume within the levels specified in the labeling.</li>\n<li>Shares are off <font color=\"red\">49%</font> premarket on increased volume.</li>\n<li>Previously: <a href=\"https://seekingalpha.com/news/2397296-adamis-pharma-gets-crl-regarding-epinephrine-pre-filled-syringe-nda-shares-tank-35-percent\" target=\"_blank\">Adamis Pharma gets CRL regarding epinephrine pre-filled syringe NDA; shares tank 35%</a> (March 27, 2015)</li>\n</ul><div class=\"tiny-share-widget\" data-id=\"3187330\" data-linked=\"Adamis Pharma&#39;s NDA for epinephrine pre-filled syringe rejected a second time by FDA; shares plummet 49% premarket\" data-tweet=\"$ADMP - Adamis Pharma&#39;s NDA for epinephrine pre-filled syringe rejected a second time by FDA; shares plummet 49% premarket https://seekingalpha.com/news/3187330-adamis-pharmas-nda-for-epinephrine-pre-filled-syringe-rejected-second-time-fda-shares-plummet?source=tweet\" data-url=\"https://seekingalpha.com/news/3187330-adamis-pharmas-nda-for-epinephrine-pre-filled-syringe-rejected-second-time-fda-shares-plummet\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3187328\" data-ts=\"1465214084\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HERO\" target=\"_blank\">HERO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3187328-hercules-offshore-files-for-bankruptcy-for-second-time-in-eight-months\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hercules Offshore files for bankruptcy for second time in eight months</a></h4><ul>     <li>Hercules Offshore (NASDAQ:<a href=\"https://seekingalpha.com/symbol/HERO\" title=\"Hercules Offshore Inc\">HERO</a>) files for Chapter 11 bankruptcy protection, just six months after emerging from its first bankruptcy.</li>\n<li>HERO had flagged the move <a href=\"https://seekingalpha.com/news/3186049-hercules-offshore-files-chapter-11-restructuring\" target=\"_blank\">last month</a> when it said it had failed to find a buyer and entered into a restructuring support agreement  with some  lenders, which will allow it eventually to place its unsold assets  into a wind-down vehicle until they can be  sold.</li>\n<li>The sale-and-shut-down plan has the <a href=\"http://www.marketwatch.com/story/hercules-offshore-files-for-bankruptcy-again-2016-06-06\" target=\"_blank\">support of nearly all the top  lenders</a> that helped it out of bankruptcy in November, according to court  papers.</li>\n<li>HERO lists assets totaling $50M-$100M and liabilities of $100M-$500M.</li>\n<li>HERO <font color=\"red\">-24.8%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3187328\" data-linked=\"Hercules Offshore files for bankruptcy for second time in eight months\" data-tweet=\"$HERO $HEROQ - Hercules Offshore files for bankruptcy for second time in eight months https://seekingalpha.com/news/3187328-hercules-offshore-files-for-bankruptcy-for-second-time-in-eight-months?source=tweet\" data-url=\"https://seekingalpha.com/news/3187328-hercules-offshore-files-for-bankruptcy-for-second-time-in-eight-months\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":40,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}